CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 200 enrolled
Drug / intervention
Consume coffee +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05121519
NCT05121519N/ACompleted

A Randomized Controlled Trial to Assess Abstinence of Coffee Compared to Continued Consumption on Recurrent Atrial Fibrillation Following Cardioversion

University of California, San Francisco·interventional·Posted Nov 16, 2021·Updated Nov 26, 2025

In Brief

A clinical study evaluating Consume coffee and Avoid coffee for Atrial Fibrillation and Coffee. Completed, enrolled 200 participants across 3 sites in 3 countries.

Detailed Summary

Given both the increasing population impact of atrial fibrillation (AF) and the widespread consumption of coffee in society, determining an associated benefit or risk of coffee consumption on AF is of great clinical relevance. This study will evaluate the effect of randomly assigning participants undergoing cardioversion to coffee abstinence or coffee continuation over a 6 month period. This study will provide the first, randomized evaluation of coffee on AF outcomes and will provide important information on whether or not coffee has any effect on AF recurrence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada, United States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 16, 2021
Enrollment StartOct 20, 2021
Primary CompletionJun 5, 2025
Study CompletionOct 20, 2025
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 4.6 years ago

Interventions

Consume coffeeother

Drink coffee regularly (recommend at least 1 cup of caffeinated coffee or one shot of espresso per day)

Avoid coffeeother

Abstain from coffee and other caffeinated products